derazantinib
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 10, 2017 (NCT03230318)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
- Fibroblast growth factor receptor 3INHIBITOR
FGFR3 inhibitor
- Fibroblast growth factor receptorINHIBITOR
Fibroblast growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCCNCCc1cccc(Nc2ncc3c(n2)-c2ccccc2[C@H](c2ccccc2F)C3)c1- Mol. weight
- 468.58 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297187 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05174650 | Phase 2 | Apr 20, 2022 | IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest |
| NCT04604132 | Phase 1/Phase 2 (Phase 2) | Oct 6, 2020 | Basilea Pharmaceutica |
| NCT04098692 | Phase 1 | Aug 8, 2019 | Basilea Pharmaceutica, Quotient |
| NCT04045613 | Phase 1/Phase 2 (Phase 2) | Jul 25, 2019 | Basilea Pharmaceutica |
| NCT03230318 | Phase 2 | Nov 10, 2017 | ArQule |
| NCT04087876 | N/A | — | Basilea Pharmaceutica |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Basilea Pharmaceutica | For profit | 4 | 4 | 3 | 2019 |
| ArQule | For profit | 1 | 1 | 1 | 2017 |
| IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Quotient | For profit | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1